QMA

PTC Therapeutics, Inc. (PTCT) — QMA analysis

Sector: Healthcare · Market cap: $6.0B · Price: $60.59 · Data as of 2026-10-23

39
/100
D
Composite grade
Higher score than 29% of 22,734 tracked stocks

PTC Therapeutics, Inc. has a below-average composite score of 39/100, higher score than 29% of 22,734 tracked stocks. The highest-scoring layer is Off-exchange trading (FINRA) / large flows; the lowest is Insider activity.

Analytical score, not investment advice. No score is an instruction or a guarantee. Past performance ≠ future results.
Share this analysis
𝕏in

What 6 data layers say about PTCT

The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.

LayerScore
Fundamental value (FVS)41/100
Technical trend (TSS)43/100
Relative strength (RS)38/100
Momentum (USS)53/100
Insider activity (IAS)10/100
Off-exchange trading (FINRA) / large flows (WHS)55/100

What does the QMA model currently show for PTC Therapeutics, Inc.?

The composite score is an entry point, not a signal. What matters is layer confluence — whether they point the same direction.

For PTCT the layers diverge — some score high (Off-exchange trading (FINRA) / large flows), others low (Insider activity). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.

PTCT insider & smart money activity

Over the recent period we record 12 reported insider purchases and 50 sales for PTCT: predominance of reported sales (by dollar value). A description of the data layer, not an instruction.

PTCT seasonality

The historically strong window for PTCT was August 1–28 with a hit rate of 71% and an average move of 6.0% (14 years of history).

Historical data does not guarantee future results.

How PTCT compares

Similar stocks from the same sector:

Frequently asked questions

What is the composite score for PTCT stock?

39/100 (grade D) as of 2026-10-23, fusing 6 data layers. An analytical score, not advice.

Are insiders buying PTCT stock?

Over the recent period, reported: purchases 12, sales 50 (purchases $3.3M, sales $21.6M). Insider activity: predominance of reported sales (by dollar value) — a description of reported data, not a trade instruction.

Where can I see live PTCT data?

Live PTCT data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.

Explore more — for free

The PTCT score is just the start. Keep going free in the QMA magazine — analysis, tools and learning with no payment up front.

Free registration, no card — trial full access, then the free plan

Want the full PTCT analysis with all layers and live data? Open PTCT detail →

Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.

⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.

Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]